Niagen Bioscience (NAGE) Operating Margin (2010 - 2026)
Niagen Bioscience (NAGE) posted quarterly Operating Margin of 5.01% for Q1 2026, down 1065.0% year-over-year from 0.52% in Q1 2025, and down 58.53% quarter-over-quarter from 12.07% in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) Operating Margin (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Operating Margin for 17 consecutive years, with 5.01% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin fell 1065.0% year-over-year to 5.01%; the TTM figure through Mar 2026 stood at 10.03% (down 223.0% YoY), while the FY2025 annual figure was 12.58%, up 482.0% from the prior year.
- Operating Margin eased to 5.01% in Q1 2026 per NAGE's latest filing, from 12.07% in the prior quarter.
- Across five years, Operating Margin topped out at 24.42% in Q4 2024 and bottomed at 44.8% in Q1 2022.
- Historically, Operating Margin has averaged 3.11% across 5 years, with a median of 1.13% in 2024.
- Annual changes were most pronounced in 2023 — Operating Margin soared 3607 bps — and 2025, when it slumped 1234 bps.
- Niagen Bioscience's Operating Margin stood at 6.88% in 2022, then jumped by 88 bps to 0.79% in 2023, then surged by 3180 bps to 24.42% in 2024, then slumped by 51 bps to 12.07% in 2025, then sank by 59 bps to 5.01% in 2026.
- Business Quant data shows NAGE's Operating Margin at 5.01% in Q1 2026, 12.07% in Q4 2025, and 12.46% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | 2.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.35% |
| Mar 31, 2026 | 5.01% |
| Dec 31, 2025 | 12.07% |
| Sep 30, 2025 | 12.46% |
| Jun 30, 2025 | 10.24% |
| Mar 31, 2025 | 15.66% |
| Dec 31, 2024 | 24.42% |
| Sep 30, 2024 | 6.26% |
| Jun 30, 2024 | -1.13% |
| Mar 31, 2024 | -3.30% |
| Dec 31, 2023 | -0.79% |
| Sep 30, 2023 | -5.88% |
| Jun 30, 2023 | -11.40% |
| Mar 31, 2023 | -8.72% |
| Dec 31, 2022 | -6.88% |
| Sep 30, 2022 | -17.96% |
| Jun 30, 2022 | -38.17% |
| Mar 31, 2022 | -44.80% |
| Dec 31, 2021 | -29.93% |
| Sep 30, 2021 | -51.08% |